OverviewThe NEMESIS laser is a medical device designed for clinical use in permanent hair reduction and the treatment of benign vascular and vascular-dependent lesions. It integrates simultaneous emission of 755 nm, 808 nm and 1064 nm wavelengths through a single handpiece to enable treatment across a broad range of skin phototypes and hair structures. The system is US FDA cleared and certified to ISO 13485:2016.
Key Features- Simultaneous triple wavelengths: one handpiece emits 755 nm, 808 nm and 1064 nm concurrently to cover multiple chromophores and hair types.
- Energy conversion technology: laser energy is converted into thermal energy to target hair follicles and vascular lesions with controlled penetration.
- Versatile indications: suitable for
- permanent hair reduction
- benign vascular lesions (e.g., port-wine stains, telangiectasias)
- vascular-dependent lesions (e.g., hemangiomas)
- Patient comfort and safety: low-fluence, high-frequency delivery for enhanced tolerability.
Benefits- Comprehensive treatment capability: addresses multiple indications with a single device.
- Targeted clinical effect: delivers controlled thermal energy for effective follicle and lesion treatment.
- Minimal downtime: procedures allow rapid recovery and clinical workflow efficiency.
- Regulatory compliance: US FDA clearance and ISO 13485:2016 certification support clinical deployment.
Technical specifications- Model name: NEMESIS
- Wavelengths: 755 nm, 808 nm, 1064 nm (simultaneous emission)
- Handpiece: single handpiece emitting three wavelengths simultaneously
- Indications: permanent hair reduction; benign vascular lesions (e.g., port-wine stains, telangiectasias); vascular-dependent lesions (e.g., hemangiomas)
- Technology: laser-to-thermal energy conversion targeting hair follicles and vascular lesions
- Treatment delivery: low fluence, high-frequency laser delivery for enhanced comfort
- Regulatory: US FDA clearance
- Certifications: ISO 13485:2016